The deal, builds on the previously announced deal and licence agreement in 2022, is intended to combine LCB’s proprietary ADC technology with one of Glycotope’s investigational antibodies
LegoChem has signed worldwide licensing agreement with Glycotope on antibody drug conjugate. (Credit: Mufid Majnun from Pixabay)
South Korea-based LegoChem Biosciences (LCB) and biotechnology company Glycotope have entered into a worldwide licencing agreement for the development of an antibody drug conjugate (ADC).
The deal is intended to combine LCB’s proprietary ADC technology with one of Glycotope’s investigational antibodies.
The latest exclusive agreement builds on the previously announced deal and license agreement in 2022.
According to the terms of the agreement, LCB has global exclusive rights to develop and market the selected antibody as an ADC.
In return, the biotechnology firm will get an upfront payment and is eligible for clinical, regulatory, and sales milestone payments, as well as royalties on net sales worldwide from the South Korean firm.
Specific financial terms related to the agreement were not disclosed.
LegoChem Biosciences CEO & president Yong-Zu Kim said: “With the licencing of the antibody for the development as an ADC, we are further expanding the number of ADCs we have under development, which demonstrates our commitment to maximising the value of our ADC payload and linker technology.
“We look forward to advancing the program to the clinical stage.”
LCB’s ADC platform technologies overcome the current limitations of antibody drug conjugates by providing a trinity of improved properties.
These features include site-specific stable bioconjugation, cancer-selective linker activation, and cancer-selective activation of potent payload in a much wider Therapeutic Window.
The antibodies of Glycotope are designed to target specific tumour-associated carbohydrate structures or protein/ carbohydrate-combined glyco-epitopes.
To provide a customised therapeutic format for as many patients as feasible, the antibodies are suitable for a multi-function platform approach with independent modes of action based on their tumour-specificity.
Glycotope CEO Henner Kollenberg said: “We are excited by the collaboration with LCB on this ADC programme.
“Our antibody discovery platform based on protein/carbohydrate combined glyco-epitopes (GlycoTargets) is constantly expanding, and it is great to see another of our antibodies being further developed in a highly potent therapeutic setting.”